p53 Expression in Biopsies From Children With Langerhans Cell Histiocytosis

Bank, Micha I; Rengtved, Pia; Carstensen, Helena; Petersen, Bodil Laub

doi:10.1097/00043426-200212000-00010

Cited by 29 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 A mutation in gene or inactivation of respective protein would result in the failure of regulation and abnormally high incidence of cells with detectable nuclear p53. 7 Expression of high levels of p53 have been reported in previous studies. 4,7,8 However, the correlation between p53 expression and manifestation of the disease is unclear.…”

supporting

confidence: 52%

“…7 Expression of high levels of p53 have been reported in previous studies. 4,7,8 However, the correlation between p53 expression and manifestation of the disease is unclear.…”

supporting

confidence: 52%

“…This is in accordance with most of the previous studies. 1,15,16 However, no significant correlation between p53 expression and extent of the disease could be detected. This finding is in accordance with the results of Amir and Weintraub.…”

Section: Discussionmentioning

confidence: 94%

See 2 more Smart Citations

VEGF and p53 Biomarkers in Pediatric Patients With Langerhans Cell Histiocytosis

Mehrazma¹,

Mahjoob²,

Ka³

et al. 2013

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

supporting

confidence: 52%

“…7 Expression of high levels of p53 have been reported in previous studies. 4,7,8 However, the correlation between p53 expression and manifestation of the disease is unclear.…”

supporting

confidence: 52%

See 1 more Smart Citation

VEGF and p53 Biomarkers in Pediatric Patients With Langerhans Cell Histiocytosis

Mehrazma¹,

Mahjoob²,

Ka³

et al. 2013

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…Lesional Langerhans cells demonstrate several characteristic phenotypic changes that differentiate them from the normal Langerhans cells. Bank et al 15 reported increased expression of wild-type 53 in the lesional Langerhans cells from 50 pathologic specimens, whereas Schouten et al 16 also demonstrated increased expression of MDM2, a negative regulator of p53, as well as p21, p16, Rb, B-cell leukemia/lymphoma 2, and the transforming growth factor A receptor. Although these data point to a possible molecular pathway, the definitive etiology remains an enigma.…”

Section: Pathophysiologymentioning

confidence: 99%

Primary Musculoskeletal Langerhans Cell Histiocytosis in Children

Arkader

Glotzbecker²,

Hosalkar³

et al. 2009

Journal of Pediatric Orthopaedics

View full text Add to dashboard Cite

There is variability of presentation in musculoskeletal LCH. Biopsy is usually indicated for diagnostic confirmation. Although the natural history for most lesions is of gradual healing, curettage and grafting are sometimes indicated to accelerate the healing process. Internal fixation for stability is occasionally necessary. Chemotherapy is used for multisystemic disease, and radiotherapy is no longer used.

show abstract

“…This was assessed in at least 8 LCH lesions with and in 8 LCH lesions without BRAFV600E mutation. Because TP53 mutations and subsequent up-regulation of mutant p53 protein have also been discussed as a pathomechanism underlying LCH, 25,26 we assessed p53 expression in the lesions by immunohistochemistry. Strong expression of p53 was seen in LCH independent of BRAFV600E mutational status ( Figure 4F; P Ͼ .19, Student t test).…”

Section: Distribution Of Brafv600e-positive Cells and Activation Of Perkmentioning

confidence: 99%

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis

Sahm

Capper

Preusser

et al. 2012

Blood

199

146

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is a clinically and histologically heterogeneous disorder. Its classification as either reactive inflammatory or neoplastic has been a matter of debate. However, the recent finding of frequent BRAFV600E mutations in LCH argues for the latter. The exact cell type that harbors the mutation and is responsible for proliferation remains to be identified. We here apply a BRAFV600E mutation-specific antibody to detect the BRAF mutant cells in lesions from 89 patients with LCH. We found BRAFV600E mutations in 34 of 89 (38%) lesions. In lesions with the BRAFV600E mutation, the majority of cells coexpressing S-100 and CD1a harbored mutant BRAFV600E protein. These cells also expressed CD14 and CD36, whereas various fractions exhibited CD207. On the other hand, CD80 and CD86 expression was also present on BRAFV600E-positive cells. Thus, cells of variable maturation, exhibiting an immunohistochemical profile compatible either with myeloid cell or with dedifferentiated Langerhans cell antigens, carry the BRAFV600E mutation. In conclusion, we identify and characterize the neoplastic cells in LCH with BRAFV600E mutations by applying a mutation-specific marker and demonstrate feasibility for routine screening. (Blood. 2012;120(12):e28-e34)

show abstract

p53 Expression in Biopsies From Children With Langerhans Cell Histiocytosis

Abstract: An increased expression of p53 in pLC indicates an altered DNA repair control with or without abnormal control of apoptosis.

Cited by 29 publications

References 15 publications

VEGF and p53 Biomarkers in Pediatric Patients With Langerhans Cell Histiocytosis

VEGF and p53 Biomarkers in Pediatric Patients With Langerhans Cell Histiocytosis

Primary Musculoskeletal Langerhans Cell Histiocytosis in Children

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis

Contact Info

Product

Resources

About